Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.66 USD
-0.03 (-1.78%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.65 -0.01 (-0.60%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 1 - 20 ( 400 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sota?s AdCom and PDUFA Dates for T1D Set at October 31 and December 20, 2024, Respectively
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Resource Optimization Boosts Ongoing Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Sota?s Franchise Expands With Near-Term and Future Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sota PDUFA for T1D Set at December 20, 2024; Commercial Preparations Ongoing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ADA Unveils Sotagliflozin?s Efficacy for Glycemic Control in T2D, and Need for Novel Treatments for DPNP
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sotagliflozin NDA Resubmission in Place for Targeted T1D +CKD Subpopulation; Potential Launch Expected in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - Dropping Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ESC Guidelines Lift Class with Recommendation of SGLT2i''s to SOC for Chronic HF
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Sota/HF NDA Filing Anticipated in H2:21, Pain Data by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY20: Eventful H2:21 - Sota/HF NDA Filing and First-Look at Pain Data
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Raising PT on HF but Requires Partner; Going Neutral as Situation Unpredictable
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L